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Abstract
Natural killer (NK) cells express many newly identified activating and inhibitory recep-
tors that upon engagement by cognate ligands on target tumor cells regulate NK cell anti-
tumor activity. Recently, several paired NK cell receptor families that include receptors 
with similar binding specificities but opposite function have been defined. The expression 
of most important activating receptors, natural killer group 2D (NKG2D), natural cyto-
toxic receptors (NCR), DNAX accessory molecule-1 (DNAM1) and activating killer cell 
immunoglobulin-like receptors (KAR) is often decreased, while the expression of most 
prominent inhibitory NK cell receptors, killer cell inhibitory immunoglobulin-like recep-
tors (KIR) and CD94/NKG2A, may occasionally be increased in malignancies. These data 
indicate that impaired NK cell antitumor response results from NK cell receptor altera-
tions induced by suppressive factors in the tumor microenvironment, including cytokines, 
growth factors, enzymes and metabolites, as well as by chronic NK cell receptor engage-
ment by the tumor. The established alterations in NK cell receptor expression in cancer 
patients represent potential disease biomarkers and may aid in choosing therapies that 
upregulate activating or block inhibitory receptor function. Accumulating knowledge of 
NK cell biology has been helpful in creating novel therapeutic approaches that by release 
from tumor-influenced immunosuppression potentiate NK cell activity in cancer patients.
Keywords: NK cells, inhibitory and activating receptors, immunosuppression, cancer, 
immunotherapy
1. Introduction
Natural killer (NK) cells are equipped with multiple activating and inhibitory cell surface 
receptors and play a key role in controlling tumor growth and metastasis. NK cells have 
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 originally been described to belong to the innate arm of the immune system and are able to 
discriminate between normal and transformed cells on the basis of major histocompatibility 
complex (MHC) class I molecule expression in the organism. As normal cells express major 
histocompatibility complex (MHC) class I molecules that engage NK cell inhibitory receptors, 
they are protected from NK cell-mediated lysis. Therefore, according to the “missing-self” 
hypothesis, activation of NK cells occurs in contact with malignantly transformed cells that 
have lost MHC class I molecules and that have additionally acquired stress-induced ligands 
for activating NK cell receptors. Maintenance of NK cell antitumor function relies on the bal-
ance between these activating and inhibitory signals mediated by NK cell receptors [1].
Considering that NK cells are defined as CD3−CD56+CD16+/− cells according to the density of 
expression of these receptors, these cells are divided into two subsets. The larger cytotoxic 
subset with high density of CD16, low density of CD56 (CD56dimCD16bright), and abundant 
perforin and granzyme granules, and the other, smaller regulatory subset with low density 
or absence of CD16, high density of CD56 (CD56 brightCD16dim/−) and the ability to produce 
abundant cytokines including interferon-gamma (IFN-γ), tumor necrosis factor (TNF), inter-
leukin (IL)-10, IL-13, and granulocyte-macrophage colony-stimulating factor (GM-CSF) [2]. 
CD56 brightCD16dimsubset has a greater migratory potential and is recruited into tumor tissue, 
although CD56 dimCD16 brightNK cells have also been detected in certain tumors [3]. Recent 
data have shown in mucosa-associated lymph tissue (MALT), the presence of a novel family 
of tissue-resident innate lymphoid cells (ILC), with NK-like characteristics. This novel fam-
ily is classified into three groups (ILC1, ILC2, and ILC3) and contrary to classical cytotoxic 
NK cells, considered to belong to ILC1 group, the involvement of other ILC subsets in cancer 
progression or resistance is still controversial [4].
Several new families of receptors have been recently identified on NK cells and growing 
knowledge indicates that some families are composed of paired receptors that inspite of bind-
ing similar ligands have opposite, activating, or inhibitory function [5]. The most important 
activating NK cell receptors are NKp46, NKp30, and NKp44 that belong to natural cytotoxic 
receptors (NCR) family, natural killer group 2D (NKG2D) that belongs to NKG2 calcium-
dependent lectin-like (NKG2 C-lectin) family, DNAX accessory molecule 1 (DNAM1) that 
belongs to the family of nectin-binding adhesion molecules and activating killer cell immuno-
globulin-like receptors (KAR). On the contrary, the most important family of inhibitory NK 
cell receptors belongs to killer cell immunoglobulin-like (KIR) receptor family, while NKG2 
C-lectin family also includes inhibitory CD94/NKG2A NK cell receptors (Table 1). Upon 
binding ligands, these activating and inhibitory NK cell receptors cooperate and determine 
NK cell cytotoxicity against transformed cells [6]. However, tumor-derived immunosuppres-
sive factors play a major role in evading NK cell responses to tumors by interfering with NK 
cell activation pathways or the complex receptor array that regulate NK cell activation and 
antitumor activity [3, 7].
The objective of this chapter is to present current data based on the knowledge of many 
newly identified activating and inhibitory NK cell receptors whose balance regulates NK cell 
antitumor activity. Numerous alterations in NK cell receptor expression and signaling path-
ways induced by tumor-derived immunosuppressive factors that are responsible for poor 
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NK cell cytotoxic function in cancer patients will be defined. Understanding of the alterations 
in NK cell receptors and function can contribute in the assessment of biomarkers of the state 
of malignant disease and may aid in the selection of immunotherapy that supports an effec-
tive NK cell antitumor response.
2. NK cell receptors
2.1. Natural cytotoxic receptors
The NCR represent a group of human NK cell activating receptors that belong to the immu-
noglobulin superfamily and include NKp46, NKp30, and NKp44. NKp46 and NKp30 are 
Receptor familes Ligands Signaling molecules
NCR Activating NKp46 HSPG, heparin, 
vimentin
FcRγ and CD3ζ, 
ZAP70/Syk
NKp44 NKp44L DAP12, ZAP70/Syk
NKp30a, b B7-H6, BAG-6 CD3ζ, ZAP70/Syk
Inhibitory NKp44 PCNA ITIM, SHP1, 2
NKp30c ? ?
Paired receptors
NKG2 Activating NKG2D MICA/B, ULBP1-6 DAP10, Grb2, Vav, 
SOS
CD94/NKG2C HLA-E DAP12, ZAP70/Syk
Inhibitory CD94/NKG2A
HLA-E ITIM, SHP1, 2CD94/NKG2E
CD94/NKG2F
KIR Inhibitory 2DL1/L2/L3 HLA-C ITIM, SHP1, 2
3DL1/L2/L3 HLA- A, -B
Activating 2DS1/S2/S4 HLA-C/? DAP12, ZAP70/Syk
3DS1 ?
Adhesion molecules Activating DNAM-1 PVR, nectin-2 ITSM, Vav, PLCγ
Inhibitory TIGIT PVR, nectin-2 ITIM, SHP1, 2
TACTILE
FcγRIII Activating CD16 Fc IgG FcRγ and CD3ζ, 
ZAP70/Syk
NKPR1 Activating CD161 ? ?
Inhibitory LLT1 ITIM, SHP1, 2
Table 1. NK cell activating and inhibitory receptors.
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 constitutively expressed on all activated and resting NK cells, whereas NKp44 expression 
on NK cells requires activation by IL-2. This makes NKp46 and NKp30 the only NK-specific 
markers known today, although recent evidence suggests that a very small subset of T cells 
expresses NKp46 [8].
Tumor-associated ligands for most NCR have only been recently described. B7-H6 was 
the first identified cellular ligand for an NCR expressed on the surface of cancer cells that 
binds to the activating receptors NKp30 [9]. Recently, a novel isoform of the mixed lin-
eage leukemia-5 (MLL5) nuclear protein was proposed as a cancer cell-expressed ligand 
for NKp44 [10]. Ligands for NKp46 have been described to have viral structural motives 
that belong to hemagglutinin-like molecules or to be heparan sulfate proteoglycans (HSPG) 
[11]. The cytoplasmatic domains of NCR do not possess any signaling motives except for 
NKp44 that contains an immunoreceptor tyrosine-based inhibition motif (ITIM) that has 
been reported functional only upon binding to certain ligands. Therefore, NCR associate 
with CD3 ζ-chain, FcεRIγ and DAP12 adaptor proteins that undergo phosphorylation of 
their immunoreceptor tyrosine-based activation motives (ITAM), recruit sarcoma homol-
ogy 2 (SH2) domains of spleen tyrosine kinase (Syc)/zeta-chain-associated protein kinase 70 
(ZAP70) and ultimately lead to extracellular signal-regulated kinase (ERK) activation and 
cytotoxic granule mobilization [8].
Conversely, it has recently been shown that the constitutively inactive cytoplasmatic ITIM 
domain of NKp44 receptor becomes functionally active only upon binding proliferating cell 
nuclear antigen (PCNA) leading to the inhibition of NK cell function [12] that might be involved 
in tumor immune evasion. Similarly, as NKp30 is comprised of three different isoforms, 
NKp30a, b, and c it has been shown that binding of NKp30c induces an immunosuppressive 
signal by producing IL-10 that is associated with reduced NK cell effector functions. Therefore, 
the final outcome of NKp44 and NKp30 activation depends on the presence of ligands on tar-
get cells, as well as receptor isoforms expressed on the surface of NK cells, respectively [13].
NCR, aside from direct antitumor cytotoxicity can also mediate the production of proinflam-
matory cytokines by NK cells that have an immunoregulatory role and engage in orchestrat-
ing antitumor immune response. In this sense, it has been shown that cross-linking of NKp46 
and NKp44 resulted in NK cell production of IFNγ and TNF that are responsible for dendritic 
cell (DC) maturation and regulation of adaptive response to tumors. However, binding of 
inhibitory NKp30c induces production of IL-10 that reduces NK cell function [14].
Downregulation of NCR expression can be induced by soluble factors such as transform-
ing growth factor beta (TGF-β), IL-10, L-kynurenine, a product of tryptophan degradation 
by tumor-derived indolamin-2,3-dioxygenase (IDO). Decreased expression of some NCR has 
been reported in several malignancies, namely low NKp46 in melanoma, pancreatic, gastric, 
cervical cancer, and acute myeloid leukemia (AML) [15–17], NKp44 in numerous solid and 
hematological malignancies, and NKp30 in breast, hepatocellular cancer (HCC), chronic lym-
phocytic leukemia (CLL), and AML [15, 16, 18–20]. Moreover, ILC3 cells expressing NKp44 
activating receptor in human nonsmall-cell lung cancer (NSCLC) tissue were shown to have 
tumor protective role [4]. However, overexpression of PCNA in certain tumors results in 
NKp44 receptor-mediated inhibition of NK cell activity [8].
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2.2. Families of paired receptors in NK cells
2.2.1. NK group 2 calcium‐dependent lectin‐like receptor family
This family of calcium-dependent lectin-like receptors includes CD94-NKG2-A/C/E/F/H het-
erodimer and NKG2D homodimer receptors present on NK cells. This family is composed of 
paired NK cells receptors with similar binding specificities to nonclassical MHC class I mol-
ecules on the surface of potential target cells but either activating or inhibitory functions [21].
2.2.1.1. Natural killer group 2D
It is an activating receptor expressed on virtually all NK cells. NKG2D recognizes a number 
of MHC-class-I-related molecules, major histocompatibility complex class I chain-related 
molecule (MIC) A/B and UL16-binding protein (ULBP) expressed on cells in stressful condi-
tions, such as transformation [22]. Owing to their ability to trigger activation of the immune 
system, it has now been shown that their expression is very tightly controlled at transcrip-
tional level [23]. NKG2D is a pivotal activating receptor that upon binding stress-induced 
ligands and phosphorylation of intracellular adaptor protein DNAX-activation protein 10 
(DAP10) recruits various signaling pathways and induces tumor cytotoxicity [24].
Decreased expression of NKG2D in cancer patients is mediated by TGFβ and IL-10 produced 
by tumor cells and immunosuppressive immune cells, tumor-associated macrophages (TAM), 
myeloid-derived suppressor cells (MDSC), regulatory T cells (Treg) in the tumor microenvi-
ronment [25]. Also, persistent stimulation of NKG2D receptor by its tumor cell-associated 
ligands, as well as, soluble ligands induced by matrix metalloproteinases (MMP) proteolytic 
cleavage from tumor cells may lead to functional exhaustion of NK cells [26].
Downregulation of NKG2D expression together with degradation of its intracellular signal 
transducing adapter, DAP10 [27], by its ligand has also been shown in experimental settings 
of conjugate formation between NK cells, not only of healthy individuals but also of met-
astatic melanoma patients, with K562, an erythromyeloid cell line, or FemX, a melanoma-
derived tumor cell line [28–30]. This effect is more pronounced for K562 tumor cells as they 
highly express MICA/B ligands specific for NKG2D receptors [31], while for FemX tumor 
cell line so far no data exist regarding the expression of MICA/B ligands, although it can be 
assumed that, as most tumor cells, this cell line expresses some level of these stress-induced 
ligands. The importance of NKG2D receptor in NK cell cytotoxic function underlies a signifi-
cant positive correlation of its expression with NK cytotoxicity in healthy individuals, as well 
as in melanoma patients, in spite of different levels of expression [32–34].
These data indicate that activating NKG2D receptor has a role in NK cell tumor immunosur-
veillance and in immune-mediated rejection of tumor cells and that NKG2D downregulation 
as a consequence of tumor immunoediting favors tumor progression [13].
2.2.1.2. Heterodimeric NK group 2 calcium‐dependent lectin‐like A/B/C/E/H receptors
These heterodimer receptors consist of CD94 subunit that is associated with the member of the 
NKG2 family (A/B/C/E/H). Prototypic member of this family CD94-NKG2A has an ITIM that 
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consequently leads to the inhibition of NK cell activity by inducing dephosphorylation of sur-
rounding tyrosine kinases and adaptor proteins. By contrast, receptors CD94-NKG2-C, CD94-
NKG2-E, and CD94-NKG2-H, associate with DAP12 and function as activating receptors that 
participate in NK cell antitumor response. These receptors bind to nonclassical MHC class I, 
human leukocyte antigen (HLA)-E molecules on the surface of malignantly transformed target 
cells [21].
Interestingly, the ligand for this receptor family, HLA-E molecule assembles at the endoplas-
mic reticulum with peptides derived from the leader peptides of HLA-A, B, C, and G mol-
ecules and as in malignant transformation, the expression of classical MHC class I molecules 
is downregulated, the expression of HLA-E is consequently upregulated [35]. The importance 
of the inhibitory activity of NKG2A receptor expression is demonstrated in breast cancer and 
colorectal cancer (CRC) as its increased expression is associated with poor disease prognosis 
[18, 36]. Conversely, decreased expression of NKG2C activating receptor resulting in NK cell 
dysfunction has so far been reported for AML [37].
2.2.2. Killer cell immunoglobulin‐like receptor family
This is a well-known paired NK cell receptor family with either inhibitory or activating func-
tions that interact specifically with MHC class I molecules and their tissue protective role is 
based on the higher binding affinity and signal transduction by inhibitory KIR receptors, 
compared to activating KAR receptors, for MHC class I ligands. According to KIR expression 
on NK cells, they are divided into KIR haplotype A and B, with A being more frequent and 
including inhibitory receptors compared to B that includes both types of receptors with pre-
dominance of activating receptors [38].
The most prominent inhibitory killer cell immunoglobulin-like receptors (KIR) are KIR2DL1 
(CD158a), KIR2DL2/3 (CD158b), and KIR3DL1-2 and inhibit NK cell activity through an ITIM 
by recruiting SH2 domain protein tyrosine phosphatases (SHP)-1 and -2 and adaptor pro-
teins, including DAP-10. Moreover, blocking actin cytoskeleton-dependent raft recruitment 
of different receptors may be a general mechanism by which inhibitory receptors control NK 
cell activation [39]. Thus, activating KAR, such as KIR2DS1, KIR2DS4,and KIR2DL4, associate 
with DAP12 adaptor protein that deliver activation signals through an ITAM that after phos-
phorylation by sarcoma (Src) family kinases recruit Syk/ZAP-70 tyrosine kinases to mediate 
downstream activation signaling [40]. Clinical studies have correlated KIR gene content with 
cancer [41]. It has recently been reported that higher expression of inhibitory CD158a and 
CD158b receptors, especially in patients that express their specific HLA-C ligands, is asso-
ciated not only with susceptibility to tumors but also with disease progression, shown by 
increase in NK cells with these receptors in advanced stages of melanoma [42, 43].
Inhibitory KIR receptor upregulation on NK cells in malignant tumors has been reported to 
be associated with immunosuppressive, as well as immunostimulatory cytokines [44–48]. 
Higher expression of certain inhibitory KIR receptors has been shown in pancreatic, gas-
tric, and CRC without association with disease progression [15]. Other studies in patients 
with metastatic melanoma, as well as in NSCLC and breast cancer, show an increase in the 
expression of CD158a and CD158b inhibitory KIR receptors on NK cells [33, 49–51] that in 
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melanoma negatively correlates with NK cell cytotoxicity [33]. In this sense, as inhibitory 
KIR play prominent roles in regulating NK cell activation therapeutic strategies designed 
to diminish KIR function that may be able to potentiate NK cell activity in treating patients 
with malignancies.
2.2.3. Family of nectin‐binding adhesion molecules
It is an important family of adhesion molecules that includes CD226 (DNAM1), CD96 (T 
cell-activated increased late expression (TACTILE)), and T-cell immunoglobulin and ITIM 
domain (TIGIT). These receptors bind nectin proteins, CD112 (nectin-2), and CD155 (polio-
virus receptor (PVR)) and have been recently identified as crucial regulators of NK cell func-
tion. This is another family of paired NK cell receptors with similar binding specificities on 
the surface of target cells but with either activating (CD226) or inhibitory (CD96 and TIGIT) 
functions [5].
2.2.3.1. Stimulatory nectin‐binding adhesion molecule
Costimulatory adhesion receptor DNAM1, a member of immunoglobulin-superfamily has 
recently been shown to have a role in the recognition of tumor cells and NK cell-mediated 
responses to tumors. It binds to PVR and nectin-2, and recruits the tyrosine kinase fibroblast 
endothelial kinase (Fyn) and serine threonine protein kinase C (PKC). Moreover, interaction of 
DNAM1 with target cell ligands induces actin polymerization and activation of other surface 
receptors, which permit stable interaction of NK cells and target cells. Furthermore, the involve-
ment of this receptor in the NK cell-mediated responses to tumors is beginning to be elucidated 
and results to date suggest that DNAM1 has a role in the recognition of tumor cells, as well as 
migration of NK cells [35, 52].
The importance of DNAM1 has been reported in breast cancer, CRC, AML, and melanoma 
[17, 18, 37, 53] and in melanoma, it has been shown that tumor-associated fibroblasts (TAF) by 
modulating the surface expression of DNAM-1 based on cell-to-cell interactions could inhibit 
NK cell function [54]. Also, DNAM1 ligand CD155 upregulation on multiple myeloma (MM) 
cells has been reported and resulted in increased sensitivity to NK cell-mediated lysis [55].
2.2.3.2. Inhibitory nectin‐binding adhesion molecules
TIGIT and TACTILE (CD96) receptors that unlike activating DNAM1 receptor contain an 
ITIM motive subsequently inhibit NK cell antitumor activity and counteract DNAM-medi-
ated activation. These receptors are important in settings in which the tumor is mainly non-
immunogenic, as it does not express stress ligands or costimulatory molecules, which is a 
common situation for many epithelial cell malignancies. For this reason, these inhibitory mol-
ecules may be promising therapeutic targets for the treatment of malignancies [5].
2.3. CD16 (Fc γ receptor IIIA)
This is one of the most important NK cell cytotoxic receptors that contains two extracellular 
Ig-like domains and is involved in both direct [56] and, as an Fc gamma receptor type IIIA, is 
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involved in antibody-dependent cell-mediated cytotoxicity (ADCC) [57], as well as cytokine 
production, proliferation, and postactivational NK cell apoptotic death [56].
CD16, as well as NKp46, associates with two cytoplasmatic domains composed of FcεRIγ 
or T-cell receptor (TCR) ζ chains that comprise ITAM, which upon ligand-binding become 
phosphorylated and induce signal transduction by activation of nonreceptor tyrosine kinases 
Syk and ZAP-70 [57].
The expression CD16 as a prominent NK cell cytotoxic receptor has been found to be decreased 
on NK cells in breast cancer and MM patients [18, 58] not only due to postactivational recep-
tor internalization but also following target cell induced activation of MMP, namely ADAM 
17, as shown during in vitro NK cell cultivation with tumor cells [59, 60]. Moreover, as CD16 
defines the two functionally different NK cell subsets, its decreased expression influences the 
ratio of these subsets, leading to the loss CD16bright cytotoxic subset, a finding that has been 
detected in numerous malignancies such as breast cancer, MM, and melanoma [6, 33].
2.4. Natural killer cell surface protein P1A
This is a member of the C-type lectin family that is primarily designated as an activating recep-
tor that plays a role in NK cell-mediated cytotoxicity and it has been previously shown that 
natural killer cell surface protein P1A (NKR-P1A)/CD161 participates in triggering NK cell 
cytotoxicity against numerous human tumor cell lines [61], while more recently, it has been 
suggested that its activating mechanism may require interaction with costimulatory receptors 
[62]. On identification of its lectin-like transcript 1 (LLT1) ligand, its inhibitory potential has 
recently been described, but its function still remains controversial. In support of the inhibi-
tory function of NKR-P1A, it has been shown that its cytoplasmic tail contains tyrosine resi-
due in an atypical motive (AxYxxL) that may function as a weak ITIM [63, 64]. There are some 
reports of decreased expression and cytokine-mediated upregulation of NKR-P1A/CD161 in 
metastatic melanoma and MM [29, 33, 58].
3. Tumor‐induced immunosuppression
It has now been well documented that tumor-induced immunosuppression affects NK cell 
receptor repertoire and leads to progressive local and systemic inhibition of NK cell func-
tion. In tumors, a complex composition of immunosuppressive molecules TGF-β, IL-10, 
IDO, prostaglandin E2 (PGE2), vascular endothelial growth factor (VEGF), nitric oxide syn-
thase (NOS), and reactive oxygen species (ROS) are produced by regulatory immune cells 
such as Treg, MDSC, TAM, and by tumor cells themselves (Figure. 1). These factors gener-
ate a chronic inflammatory immunosuppressive milieu that leads to the suppression of the 
antitumor effector NK cell function that supports tumor progression [3, 7, 13, 65]. In this 
sense, considering that the expression of activating NK cell receptors is decreased in most 
malignancies, and as some studies report that the expression of inhibitory KIR and CD94/
NKG2A receptors on NK cells in different tumors remains unchanged, this suggests that 
activating receptors are main targets of tumor-mediated suppression [13].
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Furthermore, NK cell dysfunction due to decreased activating NK cell receptor expres-
sion may be mediated by chronic tumor cell ligand-NK cell receptor engagement that 
leads to an exhausted NK cell phenotype characterized by upregulated programmed 
death 1 (PD-1) checkpoint immunoreceptor expression [66]. Conversely, the appearance 
of soluble NK cell ligands due to proteolytic cleavage from tumor cells also leads to NK 
cell dysfunction due to chronic NK cell receptor stimulation in the absence of target tumor 
cells [26].
In this sense, it has now been established that during the development of solid tumors, NK 
cells are frequently rendered functionally impaired as a consequence of cancer immunoedit-
ing that induces immune tolerance to tumors owing to impairment of NK cell receptor reper-
toire and signaling, as well as immunoselection of nonimmunogenic tumor cells.
Figure 1. Mechanisms of NK cell receptor dysregulation in tumors. The tumor induces alterations in NK cell activating 
receptors by producing suppressive tumor-derived mediators including immunosuppressive cytokines (transforming 
growth factor beta - TGF-β), enzymes (indolamin-2,3-dioxygenase - IDO), factors (L-kynurenine, prostaglandin E2 - 
PGE2) that together with the presence of hypoxia can suppress NK cell antitumor activity. Chronic engagement of NK 
cell activating receptors with either tumor cell surface-expressed or shed NK cell ligands (NKG2D ligand - NKG2D-L) 
leads to progressive inhibition of NK cell antitumor response. Also, tumor-expressed proliferating cell nuclear antigen 
(PCNA) associated with HLA-I molecule by binding NKp44 activating receptor induces unconventional inhibitory 
signals in NK cells. Moreover, interferon gamma (IFN-γ) released by NK cells induces increased expression of HLA-I 
molecules on tumor cells, as well as tumor-produced IDO, that lead to inhibition of NK cell function.
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4. NK cell receptors as therapeutic targets in cancer immunotherapy
As NK cell antitumor activity is regulated by numerous activating and inhibitory NK cell recep-
tors, alterations in NK cell receptor expression and signaling underlie diminished cytotoxic NK 
cell function. Based on this and on predictive in vitro findings [6, 46–48, 67–70], cytokines, includ-
ing IFNα, IL-2, IL-12, IL-15, and IL-18 have been used systemically or for ex vivo–activation and 
expansion of NK cells and have led to improved NK cells antitumor activity by increasing the 
expression of NK cell activating receptors and by inducing cytotoxic effector molecules [71–75]. 
Moreover, this cytokine-based therapy enhances NK cell proliferation and regulatory function, 
and it has been shown that it induces NK cells exhibiting cytokine induced memory-like prop-
erties [76] that represent a newly-defined NK cell subset with improved NK cell activity and 
longevity.
Considering the effect of tumor-derived immunosuppressive molecules on the decrease in 
the expression of activating NK cell receptors, early stage clinical trials have been introduced 
that use monoclonal antibodies, alone or in combination, to neutralize TGF-β, IDO, or PD-1 
checkpoint inhibitor in different malignancies that led to improved antitumor NK cell func-
tion [77].
Since inhibitory KIR play prominent roles in regulating NK cell activation, therapeutic strate-
gies in cancer to diminish KIR function have been developed. In autologous settings, anti-
inhibitory KIR monoclonal antibody therapy has been introduced to support autologous NK 
cell administration by rendering them with higher antitumor activity, as reported in AML 
and MM. On the other hand, allogeneic hematopoietic stem cell transplants (HSCT) based on 
partially KIR/HLA mismatched alloreactive NK cell transfer that relieve donor NK cells from 
inhibition by recipient’s MHC class I molecules, show beneficial graft-versus-tumor (GvT) 
effect in both pediatric and adult high-risk leukemia [78].
Moreover, it has been recognized that classical and novel pharmacological agents, such as 
proteasome inhibitors or histonedeacetylase inhibitors and certain chemotherapeutics [72, 74, 
75], upregulate cognate ligands for activating receptors on tumor cells and provide better NK 
cell antitumor response.
Also, a new effective approach, in clinical trials, designed to enhance NK cell—tumor cell 
interaction includes genetically modified NK cells expressing cytokine transgenes, chime-
ric antigen receptors (CARs), or overexpressing activating receptors that recognize NK cell 
ligands on tumor cells are showing promising results.
As it has been shown that therapeutic antibodies that are already in use for cancer treatment 
also trigger NK cell-mediated ADCC activity [79, 80] have been modified to increase bind-
ing of their Fc fragment to CD16 on NK cells. These therapeutic antibodies by binding CD16 
receptor induce a potent activating signal, which overcomes inhibitory signals and results in 
both cytotoxicity and cytokine responses [81] that enhance NK cell activation against tumor 
cells.
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5. Conclusion
The knowledge of NK cells has grown to include many newly identified activating and inhibi-
tory NK cell receptors and defined alterations in receptor expression and signaling pathways 
that are responsible for poor NK cell cytotoxic function in cancer patients, may be considered 
as biomarkers of the state of disease. These findings regarding NK cell receptors may aid in 
the selection of classical and newly developed therapies that favorably modulate NK cell 
receptor expression and function, and release them from tumor-derived immunosuppression 
in order to achieve an effective NK cell antitumor response.
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